1. Cyhoeddwyd

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Medi 2003.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

2. Cyhoeddwyd

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

3. Cyhoeddwyd

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D. & Hughes, D. A., 1 Meh 2003.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   Abolition of prescription charges in Wales: the impact on medicines use in those who used to pay

   Hughes, D., Groves, S., Cohen, D., Alam, M. F., Dunstan, F. D., Routledge, P. A., Hughes, D. A. & Myles, S., 1 Rhag 2010, Yn: International Journal of Pharmacy Practice. 18, 6, t. 332-340

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

5. Cyhoeddwyd

   Abolition of prescription copayments in Wales: an observational study on dispensing rates.

   Hughes, D., Cohen, D., Alam, M. F., Dunstan, F. D., Myles, S., Hughes, D. A. & Routledge, P. A., 1 Awst 2010, Yn: Value in Health. 13, 5, t. 675-680

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

6. Cyhoeddwyd

   Acceptability of generic versus innovator oral medicines: not only a matter of taste

   Tuleu, C., Hughes, D., Clapham, D., Vallet, T. & Ruiz, F., Chwef 2021, Yn: Drug Discovery Today. 26, 2, t. 329-343

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   Accounting for non-compliance in pharmacoeconomic evaluations.

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 12, t. 1185-1197

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

   Hughes, D., Hughes, D. A. & Bagust, A., 1 Tach 2002.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

9. Cyhoeddwyd

   Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam

   Hughes, D., Tach 2020, Yn: British Journal of Pharmacology. 177, 21, t. 4975-4989 15 t.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

10. Cyhoeddwyd

    Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT

    Ramanan, A. V., Dick, A. D., Jones, A. P., Hughes, D., McKay, A., Rosala_Hanna, A., Williamson, P. R., Hardwick, B., Hickey, H., Rainford, N., Kolamunnage-Dona, R., Culeddu, G., Plumpton, C., Wood, E., Compeyrot-Lacassagne, S., Woo, P., Eldesten, C. & Beresford, M. W., 10 Ebr 2019, Yn: Health Technology Assessment. 23, 15, t. 1-174 174 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

11. Cyhoeddwyd

    Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis

    Ramanan, A. V., Dick, A. D., Jones, A. P., McKay, A., Williamson, P. R., Compeyrot-Lacassagne, S., Hardwick, B., Hickey, H., Hughes, D., Woo, P., Benton, D., Edelsten, C. & Beresford, M. W., 27 Ebr 2017, Yn: New England Journal of Medicine. 376, 17, t. 1637-1646

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

12. Cyhoeddwyd

    Adherence and variability in warfarin dose requirements: assessment in a prospective cohort

    Hughes, D., Jorgensen, A. L., Hughes, D. A., Hanson, A., van Eker, D., Toh, C. H., Pirmohamed, M. & Williamson, P. R., 1 Ion 2013, Yn: Pharmacogenomics. 14, 2, t. 151-163

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

13. Cyhoeddwyd

    Adherence of patients to long-term medication: a cross-sectional study of antihypertensive regimens in Austria

    Lotsch, F., Auer-Hackenberg, L., Groger, M., Rehman, K., Morrison, V. L., Holmes, E. A., Parveen, S., Plumpton, C. O., Clyne, W., de Geest, S., Dobbels, F., Vrijens, B., Kardas, P., Hughes, D. & Ramharter, M., Mai 2015, Yn: Wiener klinische Wochenschrift. 127, 9-10, t. 379-384

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

14. Cyhoeddwyd

    Adherence with HAART: pharmacoeconomic considerations

    Hughes, D. & Hughes, D. A., 1 Meh 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

15. Cyhoeddwyd

    Advanced therapy medicinal products: a comprehensive overview for pharmacy professionals

    McKenzie, C. A., Chappel, J., Guy, R. H., Hawksworth, G., Hughes, D. & Black, A., 12 Awst 2022, Yn: Pharmaceutical Journal.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

16. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A109

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

17. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

18. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Gorff 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

19. Cyhoeddwyd

    Adverse drug reactions, multimorbidity and polypharmacy: A prospective analysis of one month of medical admissions

    Osanlou, R., Walker, L., Hughes, D., Burnside, G. & Pirmohamed, M., 4 Gorff 2022, Yn: BMJ Open. 12, 7, e055551.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

20. Cyhoeddwyd

    Adverse drug reactions: analysis by regulatory authorities and by economists

    Hughes, D. & Hughes, D. A., 1 Ebr 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

21. Cyhoeddwyd

    Affordable orphan drugs: A role for not-for-profit organisations

    Davies, E. H., Fulton, E., Brook, D. & Hughes, D., Gorff 2017, Yn: British Journal of Clinical Pharmacology. 83, 7, t. 1595-1601

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

22. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

23. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

24. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

25. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn